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Abstract: Systemic anaplastic large cell lymphomas (ALCL) are a category of T-cell non-Hodgkin’s
lymphomas which can be divided into anaplastic lymphoma kinase (ALK) positive and ALK negative
subgroups, based on ALK gene rearrangements. Among several pathways aberrantly activated
in ALCL, the constitutive activation of signal transducer and activator of transcription 3 (STAT3)
is shared by all ALK positive ALCL and has been detected in a subgroup of ALK negative ALCL.
To discover essential mediators of STAT3 oncogenic activity that may represent feasible targets for
ALCL therapies, we combined gene expression profiling analysis and RNA interference functional
approaches. A shRNA screening of STAT3-modulated genes identified interferon regulatory factor
4 (IRF4) as a key driver of ALCL cell survival. Accordingly, ectopic IRF4 expression partially
rescued STAT3 knock-down effects. Treatment with immunomodulatory drugs (IMiDs) induced IRF4
down regulation and resulted in cell death, a phenotype rescued by IRF4 overexpression. However,
the majority of ALCL cell lines were poorly responsive to IMiDs treatment. Combination with
JQ1, a bromodomain and extra-terminal (BET) family antagonist known to inhibit MYC and IRF4,
increased sensitivity to IMiDs. Overall, these results show that IRF4 is involved in STAT3-oncogenic
signaling and its inhibition provides alternative avenues for the design of novel/combination
therapies of ALCL.
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1. Introduction
Systemic anaplastic large cell lymphomas (ALCL) are a rare type of T-cell lymphoma comprising a
histologically heterogeneous group of hematopoietic neoplasms, often characterized by large cells with
variable shape (anaplastic pattern), consistently expressing the CD30 antigen [1]. ALCL accounts for
approximately 10–15% of pediatric/adolescent non-Hodgkin lymphomas (NHL) and only 2% of adult
NHL [2]. The current WHO classification of lymphoid neoplasms further subdivides systemic ALCL
into anaplastic lymphoma kinase ALK-positive (6.6%) and ALK-negative (5.5%), according to ALK
protein expression in tumor samples [3]. Whereas the oncogenic activity of chimeric ALK proteins is
considered causative of ALK-positive ALCL, the pathogenesis of ALK-negative ALCL remains less
clarified, despite recent progresses [4–9]. ALK is a membrane associated tyrosine kinase involved in
the development and function of the nervous system, where it controls cell proliferation, survival,
and differentiation in response to extracellular stimuli [4–6]. Since the discovery of ALK translocations
in ALK-positive ALCL, a variety of mechanisms leading to aberrant/ectopic ALK signaling in several
human cancers have been characterized. These include translocations or structural rearrangements,
mutations, gene amplification, and alternative transcription start sites [7,8]. The most common
alteration in ALK-positive ALCL is the t(2;5)(p23;q35) translocation that leads to the expression of
nucleophosmin (NPM)-ALK chimeric protein [9,10].
Numerous studies have demonstrated the role of ALK fusion proteins in promoting
lymphomagenesis [11–13], by constitutively activating various downstream signaling pathways, such as
janus kinase (JAK)/signal transducer and activator of transcription (STAT), phosphatidylinositol-3-kinase
(PI3K)/AKT/mammalian target of rapamycin (mTOR), RAS–extracellular signal regulated kinase
(ERK), and others [6,14,15]. STAT3 is a member of the STAT protein family. Upon cytokines and
growth factors activation, STAT family members are phosphorylated by the receptor associated
kinases, and then form homo- or heterodimers that translocate to the cell nucleus where they
act as transcription activators. In ALK-positive ALCL, it has been widely demonstrated that the
oncogenic effects of ALK chimeras are mostly mediated by STAT3 [15–19]. Gain-of-function JAK1
and STAT3 mutations have been reported in a significant proportion (∼20%) of ALK negative
ALCL [20]. These mutations were usually associated with increased phosphorylation of protein
and enhanced growth activity. Interestingly, STAT3 activation has been detected in ∼47% of ALK
negative ALCL [21], and JAK inhibitor sensitivity was correlated with the STAT3 phosphorylation
status independently of JAK1/STAT3 mutations [22]. The pleiotropic effects of STAT3 are due to
the concomitant activation/repression of multiple sets of genes, which control crucial functions,
such as cell cycle, apoptosis, motility, immune response, metabolic pathways, angiogenesis and
others [12,15,19,23–25]. In addition, STAT3 controls the expression of epigenetic modulators and
numerous microRNAs [26–28]. The strict requirement for STAT3 in a large fraction of ALCL makes
this molecule an attractive therapeutic target. However, targeting STAT3 has proven challenging and
so other potential targets in this pathway have gathered attention [29].
Here, to discover critical mediators of STAT3 oncogenic activity that may represent viable
targets for ALCL therapies, we combined gene expression profiling analysis with RNA interference
functional approaches. Transcriptional analysis identified a selected number of genes (1730) specifically
modulated by STAT3 silencing, which were grouped in 12 clusters, according to the kinetic and
direction of their modulation. Among early-regulated genes carrying conserved STAT3 binding sites
(BS) in their regulatory regions, we found that Interferon Regulatory Factor 4 (IRF4) is a key protein
involved in ALCL proliferation and survival. Overall, these findings show that IRF4 is involved in
STAT3-oncogenic signaling, and that its inhibition might represent a promising avenue for the design
of combination therapies in ALCL.
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2. Results
2.1. Kinetics of STAT3-Regulated Genes in ALCL Cell Lines
To unravel the STAT3 signaling network in T-cell lymphomas and to discover key players that
may represent feasible targets for ALCL therapies, we designed a time course gene expression profiling
experiment (GEP) using two clones (2X and 21) of the ALK positive ALCL cell line (TS-SUP-M2
S3S) which express a doxycycline-inducible STAT3 short hairpin RNA (shRNA) [27,30]. Biological
triplicates of TS-SUP-M2 S3S cells were treated with doxycycline (1 µg/mL) for 0, 24, 48, 72, 96 h.
Cells were harvested for RNA and protein extraction at different time points (Figure S1A). STAT3
silencing was confirmed by RT-qPCR (Figure 1A) and by western blotting (Figure S1B). To define
differential expressed genes, we used a filtering criteria of at least 2.0-Fold Change in expression
(FC > 2) with a differential score of p < 0.001. The top hits included transcripts previously described to
be regulated by NPM-ALK through STAT3, such as IL2RA, LEF1, ICOS, IL10, GAS1, SGK, and others
(Table S1) [30,31]. Gene expression profiling analysis identified a selected number of genes (1730)
specifically modulated by STAT3 silencing, which could be grouped in 12 clusters according to the
kinetic and direction of their modulation (Figure 1B). Kinetic analysis indicates a progressive increase
of differentially regulated genes (Figure S1C). The list of differentially expressed genes was further
compared with a previous study in which STAT3 expression was abrogated by 3 different shRNAs [30].
Overall, more than 50% of the genes overlapped between the two experiments (Figure S1D). We then
analyzed the 12 clusters for enrichment in genes carrying conserved STAT3 binding sites (BS) in their
regulatory regions (Figure S2A).
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Figure 1. Kinetics of signal transducer and activator of transcription 3 (STAT3)-regulated genes in 
anaplastic large cell lymphomas (ALCL). (A) RT-qPCR analysis shows progressive decrease of 
STAT3 mRNA levels in the anaplastic lymphoma kinase (ALK) positive cell line TS-SUP-M2 S3S 
after doxycycline treatment (1 µg/mL). Pellet were collected at 72, 96, 120, 144 h. Error bars represent 
the standard deviation (s.d.) of triplicate measurements. (B) Heatmap representation of gene 
expression profile analysis after STAT3 inducible knockdown in the ALK positive cell line 
TS-SUP-M2 S3S. Biological triplicate were used for each experimental condition. Hybridization was 
carried out on HumanHT-12 v4.0 Expression BeadChip (Illumina Inc., San Diego, CA, USA). STAT3 
Figure 1. Kinetics of signal transducer and activator of transcription 3 (STAT3)-regulated genes in
anaplastic large cell lymphomas (ALCL). (A) RT-qPCR nalysis shows progressive decrease of STAT3
mRNA levels in the anaplastic lymphoma kinase (ALK) positive cell line TS-SUP-M2 S3S after doxycycline
treatment (1 µg/mL). Pellet were collected at 72, 96, 120, 144 h. Error bars represent the standard deviation
(s.d.) of triplicate measurements. (B) Heatmap representation of gene expression profile analysis after
STAT3 inducible kn ckdown in the ALK positive cell line TS-SUP-M2 S3S. Biological triplicate were
used for each experimental condition. Hybridization was carried out on HumanHT-12 v4.0 Expression
BeadChip (Illumina Inc., San Diego, CA, USA). STAT3 modulated genes were grouped in 12 clusters.
Upregulated RNAs are shown in red, downregulated RNA are shown in green. The colour bar represents
relative gene expression changes. In brackets are shown genes selected for functional validation.
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To this end, we exploited a positional weight matrix (PWM) approach, as previously described [32].
As a result, Cluster 7 (early down-regulated genes) showed a strong over-representation of putative
STAT3 BS. This cluster includes 82 genes bearing one BS and 54 genes carrying two STAT3 BS, with a p
value of 0.00082 and 0.00043, respectively (Figure S2B).
2.2. Functional Validation of STAT3 Target Genes
Many genes transcriptionally regulated by STAT3 in ALCL cells display unknown functions or
have never been related to oncogenic activities in T cells. Therefore, to dissect the signaling cascade
mediated by STAT3, we undertook a functional screening by RNA interference focusing on cluster
7, which includes early regulated genes, enriched for STAT3 BS. Based on literature searches and
predicted functions, 13 genes of cluster 7 were selected as candidates expected to promote proliferation
and/or survival of ALCL cells, via a direct STAT3 regulation (Table S2). We systematically analyzed
their biological functions by a lentiviral shRNA screening employing at least 5 shRNA sequences for
each target gene. To recognize genes actively driving the oncogenic properties of STAT3 in ALCL
cells, we monitored biological effects of each gene knockdown using as readouts cell proliferation,
survival and morphology. Positive hits were selected according to the following criteria: more than
one shRNA sequence was needed to reduce target mRNA levels by at least 70%; a correlation between
the proportion of gene silencing and the phenotype was required. IL-2 inducible T-cell Kinase (ITK)
and Interferon regulatory factor 4 (IRF4) genes fulfilled both criteria showing a strong phenotype
related to the silencing effects of three independent shRNAs (Table S3).
2.3. IRF4 is Required for Proliferation and Survival of ALCL Cells
To study more in detail the role of IRF4 in ALCL cells, three shRNA sequences (45A, 45B, 45E)
directed against human IRF4 were individually transduced into TS-SUP-M2 S3S cells. RT-qPCR and
immunoblotting analyses revealed that IRF4 mRNA and protein levels significantly decreased in
cells transduced with IRF4-directed shRNA, as compared to untransduced cells or cells transduced
with control shRNA sequences (Figure 2A). A time course experiment revealed that IRF4 depletion
significantly affected cell survival, as compared to controls (Figure 2B). To demonstrate the specificity
of gene knock-down, we showed reversion of toxicity by ectopic expression of IRF4 or by concomitant
use of a shRNA targeting the untranslated region of the respective mRNA (Figure 2C,D). On the
contrary, expression of a shRNA-resistant ITK failed to rescue cells from apoptosis (data not shown).
Together, these results demonstrate the requirement of IRF4 for growth and survival of ALCL cells
and suggest that shRNA “off target” effects might be responsible for the cell death-induced by ITK
knock-down [33].
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after doxycycline treatment (Figure 4B). To elucidate IRF4-mediated cell death prevention, we analyzed
proteins involved in cell cycle and apoptosis. As shown in Figure 3B, no significant changes in cyclin
D3, cyclin A, and cyclin B1 protein levels could be detected. On the contrary, ectopic IRF4 expression
decreased cleavage of the caspases substrate poly (ADP ribose) polymerase 1 (PARP1), as compared
to control. Accordingly, propidium iodide (PI) staining identified a lower proportion of hypodiploid
cells, indicative of apoptosis, in IRF4 expressing cells (19.5%), as compared to untransduced (56%),
and to empty vector (59.5%) conditions (Figure 3C). Overall, these experiments indicate that IRF4 is
involved in cellular process essential for the survival of ALK positive ALCL cells.
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Figure 4. IRF4 partially mediates STAT3 oncogenic properties in ALCL cells. (A) TS-SUP-M2 S3S
cells were transduced with lentiviral particles expressing human IRF4 open reading frame (ORF),
an empty vector (EV), or left untransduced (UTR) as negative controls. Cells were cultured in the
presence of 1 µg/mL doxycycline to induce STAT3 KD. Kinetics of cell death induced by conditional
STAT3 KD revealed that cells expressing IRF4 displayed lower apoptotic rates compared to controls.
Apoptosis analysis was performed by TMRM staining-flow cytometry at the indicated time points
after doxycycline treatment. Error bars represent the s.d. of triplicate measurements (*** p < 0.001).
(B) Western blot analysis of the experiment described above revealing that IRF4 over-expressing cells
display lower levels of processed PARP, and invariant levels of cyclin A, B1 and D3 following STAT3
KD as compared to control cells. (C) Propidium iodide staining analysis of the experiment described
above indicating that IRF4 over-expressing cells display reduced sub-G0/G1 fraction, indicative of
decreased apoptosis. These findings are representative of three independent experiments.
2.5. ALCL Cell Lines Display Heterogeneous Sensitivity to Immunomodulatory Drugs
It has been demonstrated that immunomodulatory drugs (IMiDs) such as lenalidomide and
pomalidomide inhibit auto-ubiquitination of the E3 ubiquitin ligase cereblon (CRBN), leading to the
degradation of Ikaros family targets and IRF4 [34–36]. We therefore wondered whether treatment
with IMiDs could mimic IRF4 KD phenotype in ALCL cell lines. We observed that lenalidomide and
pomalidomide treatments downregulated IRF4 expression and increased cell death in TS-SUP-M2
S3S cells. Conversely, overexpression of IRF4 completely rescued apoptosis induced by lenalidomide
and pomalidomide (Figure 5), suggesting that IMiDs effects are mediated at least in part via IRF4
down-regulation. However, having extended these analyses to a larger number of ALCL cell lines, we
observed that only TS-SUP-M2 S3S cells were sensitive to pomalidomide, as revealed by cell cycle,
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apoptosis, and cell metabolism markers (Figure S4). These data suggest that each ALCL may have
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performed with ImageJ software. (B–C) Viability of TS-SUP-M2 S3S cells transduced with IRF4 ORF, 
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that IRF4 regulates its expression [37]. Moreover, it has been recently demonstrated that IRF4 and 
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Figure 5. Immunomodulatory drugs downregulate IRF4 expression and increase cell death in
TS-SUP-M2 cells. (A) TS-SUP-M2 S3S cells were transduced with human IRF4 ORF or with an empty
vector (EV) and treated with the indicated concentrations of lenalidomide or pomalidomide. Western
blot analysis revealed IRF4 downregulation after po alidomide treatment both at 3 µM and 10 µM.
Pellet for western blot were collected 4 days after treatment. Quantitative densiometric analysis were
performed with ImageJ software. (B,C) Viability of TS-SUP-M2 S3S cells transduced with IRF4 ORF,
empty vector (EV) or untransduced (UTR) as negative controls. Cells were treated with the indicated
concentrations of lenalidomide, pomalidomide, diluent (DMSO), or left untreated (NT). Analysis of cell
death revealed that ectopic expression of IRF4 completely rescued apoptosi induced by lenalidomide
and pomalidomide. Apoptosis analysis was performed by TMRM staining-flow cytometry 6 days post
treatments. Error bars represent the s.d. of triplicate measurements (** p < 0.01; *** p < 0.001).
2.6. The Bromodomain and Extra-Terminal (BET)-Inhibitor JQ1 Sensitizes ALCL Cells to
Pomalidomide Treatment
Numerous studies h ve shown that c-MYC is essential for multiple myelo a cell survival and
that IRF4 regulates its expression [37]. Moreover, it has been r cently demonstrated tha IRF4 and
MYC signaling play an essential role ALCL cell lines survival [38] and that the treatment with BET
family inhibitors may have a therapeutic efficacy in ALK positive ALCL [39]. Therefore, we tested
whether the combination of pomalidomide with the BET family inhibitor JQ1, which inhibits MYC and
IRF4 expression, could sensitize ALCL cells to IMiDs treatment. As shown in Figure 6, combination
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of the two drugs significantly increased cell death of Karpas-299, L82, SU-DHL-1 and FePd cells, as
compared to single treatments. TS-SUP-M2 S3S, which are already sensitive to pomalidomide, did
not show any significant change with the combination (Figure S5A). On the contrary, JB6 cells were
resistant to both treatments (Figure S5B, left panel). Western blot analysis revealed that in this cell line
the protein levels of IRF4 and c-MYC were not significantly downregulated by pomalidomide and JQ1
(Figure S5B, right panel).
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Figure 6. The bromodomain and extra-terminal (BET)-inhibitor JQ1 sensitizes ALCL cells to
Pomalidomide treatment. Apoptosis and western blot analysis of KARPAS 299 (A), L82 (B), SU-DHL-1
(C) and FePd (D) cells treated with DMSO, pomalidomide, the BET inhibitor JQ1, or the combination
of the two drugs. Cell death analysi revealed increa ed sensi ivity to pomalidomide in combination
with JQ1 (left panels) which correlates with a stronger down-regulation of IRF4 and c-MYC protein
levels (right panels). Error bars represent the s.d. of triplicate measurements (** p < 0.01; *** p < 0.001).
Pellet for western blot were collected 48 h after treatments.
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Paradoxically, we observed that JQ1 treatment resulted in the upregulation of IRF4 protein levels
in JB6 cells, highlighting a possible feed-back loop between the two proteins, and potentially explaining
the resistance of these cells to treatments. Taken together, these results show that IRF4 and MYC
synergic inhibition can be exploited as therapeutic strategy in ALCLs.
3. Discussion
ALCL are a rare, heterogeneous group of non-Hodgkin lymphomas with an aggressive disease
course and poor overall survival. Even though ALK positive and ALK negative ALCL show
distinctive genomic alterations, the two entities are phenotypically similar and share significant
biological and molecular key aspects. In particular, transcription factors activation, gene expression
and epigenome profiles largely overlap in both ALCL entities [30,40–44], suggesting a common
pathogenic mechanism. Among several oncogenic pathways, the constitutive activation of STAT3
is pathognomonic of ALK positive ALCL and it is detectable in ~50% ALK negative ALCL, as a
consequence of JAK1/STAT3 mutations or aberrant cytokine receptor signalling [21]. STAT3 has been
recognized a potentially promising target for therapy in ALCL and many other cancers. However, few
STAT3 inhibitors achieved in vivo evaluation, and alternative targets in this pathway are currently
under investigation [29].
Here, to dissect the STAT3 signaling network and to discover key players that may represent
feasible targets for ALCL therapies, we performed a time course gene expression profiling experiment
following conditional STAT3 knock-down. Transcriptional analysis identified 1730 genes specifically
modulated by STAT3 silencing. The list included transcripts regulated by NPM-ALK dependent STAT3
signaling, as previously described [30,31]. Overall, more than 50% of the genes overlapped between
the two studies. Notably, more than 60% of differentially expressed genes were up-regulated after
STAT3 ablation, suggesting that STAT3 may also act as transcriptional repressor. Clustering analysis
indicated that early-modulated genes were significantly enriched for conserved STAT3 binding sites in
their regulatory regions, and therefore more likely to act as direct STAT3 targets.
A functional screening by RNA interference targeting selected STAT3-regulated genes indicated
that modulation of a single gene was usually not able to establish a remarkable phenotype in ALCL
cells. A moderate growth disadvantage was induced either by BATF3 or ATF3 silencing (Table S3).
These observations are in line with recent data which suggest that both ATF3 [9] and components of
AP-1 transcription factor network act in concert, and a global AP-1 inhibition is required to cause death
of ALCL cells [45]. Two genes (ITK and IRF4) showed a strong phenotype with multiple shRNAs.
However, only IRF4 rescue assays restored cell viability and confirmed the specificity of shRNA
experiments. Thus, we interpreted the toxicity caused by ITK silencing as a potential off-target effects
related to shRNA sequences, and focused on IRF4.
IRF4 is a member of the interferon regulatory factor family of transcription factors whose
expression is restricted to the lymphoid and myeloid compartments and is not regulated by type I or
type II interferons [46]. IRF4 was demonstrated to direct the development, maturation, and terminal
differentiation of B cells and to play essential roles in orchestrating T cell fate decision [47,48].
Numerous evidences have implicated IRF4 as an oncogenic driver and potential target for inhibition
by anti-cancer agents. The first association with cancer came from the identification of a chromosomal
translocation that juxtaposes the immunoglobulin heavy-chain locus to IRF4 in multiple myeloma
patients [49]. Recurrent translocations involving IRF4 locus were also identified in T-cell lymphomas
such as PTCL-NOS and cutaneous ALCL [50]. Moreover, it was previously shown that the large
majority of primary ALCL patient samples stained positive for IRF4 irrespective of ALK translocations,
thus suggesting an important role for IRF4 in the pathogenesis of T-cell lymphomas [38]. Finally, IRF4
is required for the survival of myeloma cancer cells lacking IRF4 translocations or overexpression, by a
mechanism described as “non-oncogene addiction” [37].
Our experiments indicate that IRF4 knock down affects cell viability of ALK positive ALCL
cells, thus suggesting that IRF4 could be involved in STAT3-mediated transformation and/or play
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a relevant role in the maintenance of the ALCL neoplastic phenotype. Analyses of IRF4 expression
at transcriptional and protein level demonstrated that STAT3 knock-down is followed by IRF4
down-regulation. Computer analysis of the human IRF4 promoter revealed several putative STAT3
binding sites. These sites were found to be functional by STAT3 ChIP-seq experiments, supporting
previous indications that IRF4 expression is under STAT3 control [48,51].
We further demonstrated that IRF4 partially contributes to the ALCL oncogenesis mediated via
STAT3. In fact, cells transduced with human IRF4 exhibited lower apoptotic rate following STAT3
down-regulation. However, since the induction of apoptosis relies on a fine balance between pro- and
anti-apoptotic proteins, the evaluation of IRF4 effect on the level of several survival regulating proteins
should be more deeply investigated.
Finally, to evaluate whether IRF4 signaling can be exploited therapeutically in the ALCL context,
we tested the sensibility of several ALCL cells to IMiDs, such as lenalidomide and pomalidomide,
that indirectly downregulate IRF4 [34,36,52]. Previous studies have shown an important role of
IMiDs in numerous types of cancer, including multiple myeloma (MM), activated B-cell diffuse
large B cell lymphoma (ABC-DLBCL), and acute myeloid leukemia (AML) [53–56]. IMiDs have
numerous antitumoral effects, including immunomodulatory, anti-proliferative and pro-apoptotic
effects [56]. We established the relationship between IMiDs and IRF4 in one ALK-positive ALCL cell
line (TS-SUP-M2 S3S), and we found that lenalidomide and pomalidomide led to increased apoptosis.
Moreover, IRF4 overexpression rescued pomalidomide toxic effects, highlighting the pivotal role of
IRF4 in the survival of ALK-positive ALCL cells. However, further analysis revealed that only a
minority of ALCL cell lines were sensitive to pomalidomide. In recent years, different studies have
tried to explain IMiDs resistance. However, the molecular mechanisms are poorly understood and
they may be related to the pharmacological properties of different drugs and the cell lineage. It has
been previously reported that the deregulation of IMiDs’ targets, such as CRBN, or its substrates IRF4,
IKZF1 and IKZF3 might affect the sensitivity to this class of drugs [34,52,53,57–59]. Moreover, C/EBPβ
over-expression or β-catenin up-regulation have been described as additional mechanisms of IMiDs
resistance [60,61]. In line with these observations, it is conceivable that also in ALCL IRF4-dependent
and/or alternative mechanisms of IMiDs insensitivity might exist.
It has been recently demonstrated that IRF4 and MYC signaling play an essential role ALCL
cell lines survival [38,39]. Interestingly, the possibility of combinatorial block of MYC and IRF4 gene
expression was greatly advanced by the demonstration that treatment of multiple myeloma tumor
cells with the BET-bromodomain inhibitor JQ1 led to loss of BRD4 at super-enhancers, and consequent
transcription elongation defects of genes with super-enhancers, including MYC and IFR4 [62]. Indeed,
numerous studies have demonstrated, both in vitro and in vivo, the synergistic antitumor activity of
IMiDs and BET-bromodomain inhibitors [63–66]. We observed that the combination of pomalidomide
with the BET family antagonist JQ1 has additive effects in four of five pomalidomide-insensitive
cell lines. Further analyses, as well as in vivo studies, are needed to confirm the efficacy of IMiDs
and BET-bromodomain inhibitors combination therapy in ALCL and other tumors with de-regulated
IRF4 [67]. Importantly, our data confirm the study by Weilemann et al., that demonstrated a key role
of IRF4 in ALCL, irrespective of ALK status [38].
Here, we demonstrated the essential link between STAT3 and IRF4 expression, which could
explain the sensitivity to IRF4 inhibition also in a fraction of ALK-negative ALCL [68]. This evidence
is emphasized by the fact that STAT3 activation could be detected in almost 50% of ALK-negative
ALCL [21]. On the other hand, previous works indicated that IRF4 is expressed in the majority (>90%) of
primary ALCL cases [38,69]. These data are in agreement with the notion that IRF4 transcription could
be activated by several factors such as NF-κB and STAT5 [38,70]. We proved that IRF4 mediates the
oncogenic effects of STAT3 in ALCL, and speculated that its inhibition might represent an alternative
avenue to interfere with STAT3 signaling. It is important to emphasize that IRF4 deficient mice have no
obvious phenotypes outside of the lymphoid and myeloid lineages, in agreement with the restricted
expression of IRF4 in these cell types. Therefore, potential therapies aimed at IRF4 inhibition are
Cancers 2018, 10, 21 12 of 19
expected to be potentially manageable. In view of the above considerations, we ultimately envision
that combination therapies using JAK/STAT3 inhibitors associated to BET-bromodomain inhibitors
might offer a promising therapeutic strategy to overcome therapy resistance in ALCL patients.
4. Materials and Methods
4.1. Cell Lines and Culture Conditions
Human ALCL cells TS-SUP-M2 S3S, SU-DHL1, JB-6, KARPAS-299, FePd, and human T-ALL cells
CCRF-CEM were cultured in RPMI 1640 (Sigma-Aldrich, St. Louis, MO, USA) medium supplemented
with 10% fetal calf serum (Lonza, Rockland, ME, USA), 2 mM glutamine, 100 U/mL penicillin and
100 µg/mL streptomycin (Eurobio Biotechnology, Les Ulis, France). TS-SUP-M2 S3S (inducible cell
line derived from TS-SUP-M2) were generated as described elsewhere [12,27,30]. Human embryonal
kidney cells HEK-293T (ATCC, Manassas, VA, USA) were cultured in Dulbecco modified Eagle medium
(DMEM) with identical supplements. Cell lines were incubated at 37 ◦C in humidified atmosphere,
with 5% CO2.
4.2. shRNA Sequences, cDNA, and Plasmid Constructs
To stably knock down the expression of target genes we used specific shRNA cloned in the
lentiviral vector pLKO-Puro. shRNAs (from A to E) (Table S4) were acquired from the Lentiviral
Expression TRC Library (Sigma-Aldrich). Sense strand shRNA sequences for each gene are reported
below. Replication-deficient lentiviral expression constructs for IRF4 were generated first by cloning the
full-length cDNA of human IRF4 (acquired from Dharmacon, Lafayette, CO, USA) into pENTR1A no
ccDB (Eric Campeau, http://ericcampeau.com/). Subsequently, lentiviral destination vector pLX303
h-IRF4 was generated recombining pENTRY vectors and pLX303 with LR reaction (Gateway System,
Invitrogen, Carlsbad, CA, USA).
4.3. Virus Production and In Vitro Transduction
High titer lentiviral vector stocks were produced in HEK-293T cells by co-transfecting the
expression vector (pLKO or pLX303) and the packaging vectors 8.74 and VSV-G/pMD2.G with
the Effectene reagent (Qiagen, Hilden, Germany), according to the manufacturer’s instructions.
Supernatants were harvested over 36 to 60 h, filtrated (0.22-µm pore), and used directly or after
viral concentration by ultracentrifugation (50,000× g for 2 h). Virus titers were assessed by transducing
TS-SUP-M2 cells with serial dilutions of viral stocks. Aliquots of virus were used to infect exponentially
growing cells (1× 105/mL) in the presence of 8 µg/mL of polybrene. Fresh medium was supplemented
3–4 h after the infection. Stably transduced cells expressing shRNAs were selected by treatment
with 2 µg/mL of puromycin (Sigma-Aldrich) for 24 h. The infectivity was determined (after 24 h)
by FACS analysis of vital cells by TMRM staining-flow cytometry. For the reconstitution assay,
exponentially growing TS-SUP-M2 cells were infected with 40 µL of lentiviral particles expressing
human IRF4, or an empty vector (EV). Stably transduced cells were selected by treatment with
5 µg/mL Blasticidin (Sigma-Aldrich) for 48 h, expanded for 96 h, and plated for the infection with
specific pLKO-Puro-shRNAs.
4.4. Reverse Transcription-Quantitative Polymerase Chain Reaction (RT-qPCR)
Total RNA was extracted using the Trizol reagent (Invitrogen) or the RNeasy total RNA Isolation
Kit (Qiagen), according to manufacturer’s instructions. RT-qPCR was performed with a Thermal
iCycler (Bio-Rad Laboratories, Hercules, CA, USA) using the iQ SYBR Green Supermix (Bio-Rad
Laboratories) according to the manufacturer’s instructions. The PCR cycling conditions were as
follows: 95 ◦C for 5 min followed by 40 cycles at 94 ◦C for 10 s and 60 ◦C for 30 s. The oligonucleotide
primer pairs used for RT-qPCR, reported in Table S5, were designed to obtain amplicons of 80–150 bp.
To confirm the amplification specificity, the PCR products were subjected to the analysis of melting
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curve, linearity and slope of standard curve. All PCR assays were performed in triplicate. The results
were analyzed using the comparative ∆Ct method as described by Schmittgen and Livak [71].
4.5. Immunoblotting
Whole cell extracts were prepared by resuspending the cell pellets in lysis buffer containing
20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 5 mM EDTA, 0.1% Triton X-100, 1 mM phenyl-methyl-sulfonyl
fluoride (PMSF), 10 mM NaF, 1 mM Na3VO4, and protease inhibitors (Roche, Mannheim, Germany)
and incubated at 4 ◦C for 30 min. Cell lysates were collected by centrifugation at 15,000× g.
Supernatants were analyzed for protein concentration with a DC protein assay kit (Bio-Rad) and stored
at −80 ◦C. Twenty micrograms of proteins were separated by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) and transferred onto nitrocellulose membranes. The filters were
first blocked for 1 hour at room temperature with 5% low-fat milk in phosphate-buffered saline
(PBS) solution with 0.1% Tween 20, and then incubated with the primary antibodies for 1 h at room
temperature. After 3 washes, filters were incubated with horseradish peroxidase-conjugated goat
anti-mouse or anti-rabbit antibodies (1:10,000; Amersham, Arlington Heights, IL, USA) for 1 h at room
temperature. Immune complexes were detected with sheep-anti mouse or anti-rabbit Ig antibodies
conjugated to horseradish peroxidase (Amersham) and visualized by enhanced chemiluminescence
reagent (Amersham) according to the manufacturer’s protocol. The following antibodies were
used: mouse anti-β-tubulin (#T4026); rabbit anti-actin (#A5060) (Sigma-Aldrich); rabbit anti-c-MYC
(Cell Signaling, Danvers, MA, USA); mouse anti-STAT3 (Zymed, South San Francisco, CA, USA),
mouse anti-IRF4 (Agilent, Santa Clara, CA, USA), rabbit anti-PARP H-250 (Santa Cruz Biotechnology,
Dallas, TX, USA), rabbit anti-cyclin A (H-432) (Santa Cruz Biotechnology), rabbit anti-cyclin B (H-433)
(Santa Cruz Biotechnology), mouse anti-p27[kip-1] (BD Biosciences, San Jose, CA, USA).
4.6. Flow Cytometry Analysis of Apoptosis and Cell Cycle
Apoptosis was measured by flow cytometry after staining with the mitochondrion-permeable,
voltage sensitive dye Tetrametylrodamine methyl ester (TMRM, Molecular Probes, Eugene, OR,
USA) [68]. 5 × 105 cells were washed once in phosphate-buffered saline (PBS), incubated for 15 min at
37 ◦C in HEPES buffer solution (10 mM HEPES pH 7.4, 140 mM NaCl, 2.5 mM CaCl) with 200 nM
TMRM. Cells were analyzed by FACSCalibur, using CellQuest software (BD Pharmingen Biosciences,
San Jose, CA, USA). For cell cycle analysis and DNA content determination, cells were fixed for
1 h in 70% ethanol at 4 ◦C. After washing with PBS, cells were treated with RNase (0.25 mg/mL),
stained with propidium iodide (50 µg/mL) for 30 min. Then cells were analyzed by FACSCalibur.
The subG1/G0-phase fraction was calculated using CellQuest program (BD Pharmingen Biosciences).
4.7. ATPlite Assay
ATPlite assay was performed using CellTiter-Glo® Luminescent Cell Viability Assay (Promega,
Madison, WI, USA) to measure cell viability/proliferation. For each experiment cells were plated at
a density of 1 × 105/mL and cell proliferation was measured at day 0, day 3 and 5. 50 µL of cells
were mixed with an equal volume of CellTiter-Glo® Reagent solution per well in 96-well black plate,
in triplicate. Plate was shaken in the dark for 2 min and then incubated at room temperature for 10 min.
Luminescence was measured using a TopCount NXT Microplate Scintillation and Luminescence
Counter (Packard BioScence Company, Meriden, CT, USA).
4.8. Lenalidomide, Pomalidomide and JQ1 Treatments
Lenalidomide, pomalidomide and JQ1 were obtained from Selleck Chemicals (Houston, TX,
USA). Compounds were dissolved in 100% dimethyl sulfoxide (DMSO) before further dilution in cell
culture media. Final DMSO concentrations were manteined at 0.1% for all samples, including controls.
Exponentially growing cells were plated at a density of 1× 105/mL and treated with increasing doses of
lenalidomide, pomalidomide or JQ1 (with pomalidomide treatment refilled every 48 h). Apoptosis and
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cell proliferation was measured by flow cytometry after staining with the mitochondrion-permeable
voltage sensitive dye tetrametylrodamine methyl ester (TMRM) and ATPlite assay, respectively. At
the indicated time points pellet was collected and whole-cell extracts were subjected to western
blot analysis.
4.9. Gene Expression Profiling
TS-SUP-M2 S3S were treated with doxycycline (1 mg/mL) to induce short shRNA expression,
and monitored for green fluorescent protein (GFP) expression by FACS analysis. STAT3 was
monitored by western blotting. Biological triplicates were used for each experimental condition.
Total RNA was isolated using the Trizol reagent (Invitrogen) and purified using the RNeasy total
RNA Isolation Kit (Qiagen). RNA integrity was evaluated by an Agilent 2100 Bioanalyzer (Agilent
Technologies, Palo Alto, CA, USA). cDNA and biotinylated cRNAs were generated by Illumina Total
Prep RNA Amplification Kit (Ambion, Austin, TX, USA), in accordance to manufacturer’s indications.
cRNAs quality and quantification was assessed by Bioanalyzer. Hybridization was carried out on
HumanHT-12 v4.0 Expression BeadChip (Illumina Inc.). Array washing, staining and scanning were
performed using standard Illumina protocols. Detection data were processed with the BeadStudio
software (Illumina Inc.) using the following thresholds for significant detection: Differential Score > 30
(equivalent to p < 0.001), Detection > 0.99, Fold Change > 2.
4.10. Chromatin Immunoprecipitation-Sequencing (ChIP-seq)
A total of 4× 106 cells were fixed with 1% formaldehyde, lysed, and sonicated (Branson Sonicator;
Branson Ultrasonics, Danbury, CT, USA) leading to a DNA average size of 200 bp. 5µg of antibodies
anti-STAT3 #4904 (Cell Signaling), H3K4me3 (ab8580, Abcam, Cambridge, UK) H3K27Ac (ab177178,
Abcam), H3K27me3 (ab6002, Abcam), or control IgG #2729 (Cell Signaling) were added to the
precleared sample and incubated overnight at 4 ◦C. The complexes were purified using CHIP-grade
protein-G magnetic beads #9006 (Cell Signaling), followed by elution from the beads and reverse
cross-linking. DNA was purified using PCR purification columns (Qiagen) and target control genes
(TNFRSF8 and GAPDH were amplified by real-time quantitative PCR using SYBR Green (Bio-Rad,
#1725272). The oligonucleotide primer pairs are reported in Table S5. Raw ChIP-Seq samples were
aligned using bwa aligner. Peak calling was performed using Model-based Analysis of ChIP-Seq
(MACS Version 2.1.1, [72]), an open source computational algorithm for identifying genome-wide
protein-DNA interaction from ChIP-Seq data (https://github.com/taoliu/MACS). Only peaks with
FDR < 0.05 were called as significantly enriched. Signal tracks were created using MACS2 bdgcmp
command. Peak enrichment relative to IgG was calculated in bedgraph format and then converted to
bigwig using UCSC toolkit.
4.11. Statistics
Statistical analysis was performed with a paired, 2-tailed Student t test. p < 0.05 were considered
statistically significant. Data presented with column graphs and error bars represent average ± SD.
5. Conclusions
Overall, these data indicate that IRF4 sustains the oncogenic properties of STAT3 in T-cell
lymphomas, and that its inhibition represents an alternative avenue to interfere with STAT3 signaling
and offers promising therapeutic opportunities to treat and prevent drug resistance in ALCL patients.
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Figure S1. Kinetics of STAT3-regulated genes in the ALK-positive ALCL cell line TS-SUP-M2. (A) 
Experimental design of the gene expression profile (GEP) experiment. Two clones (2X and 21) of the 
ALKpositive ALCL cell line (TS-SUP-M2 S3S) expressing a specific doxycycline-inducible STAT3 
short hairpin RNA (shRNA) were used [27]. Biological triplicates of TS-SUP-M2 S3S cells were 
cultured in the presence (+DOX) or absence (−DOX) of doxycycline (1 µg/mL) for 0, 72, 96, 120, 144 
h, and harvested for RNA and protein extraction. RNA was labeled by Illumina Total Prep RNA 
Amplification Kit, and hybridized on Illumina HumanHT-12 BeadChip Array. (B) STAT3 silencing 
was confirmed by western blotting at the indicated time points. (C) Differential Expressed Genes 
(DEG) for each time point. In total 1730 genes were modulated after STAT3 KD. Differential score: p 
< 0.001 and FC > 2. (D) Percentage of overlapping DEG with a previous STAT3 knock down GEP 
experiment performed with 3 different shRNAs [30]. 
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Figure S2. Enrichment of putative STAT3 binding sites in cluster 7 (early down-regulated genes). 
(A) The position weight matrix (PWM) STAT3 sequence logo obtained as described by Vallania et 
al, 2009 [32]. (B) The number of genes carrying putative STAT3 binding sites is represented for each 
cluster of genes regulated by STAT3 inducible knockdown in the cell line TS-SUP-M2 S3S (P = p 
value). Each human gene is associated with a score which is the sum of the conservation scores of the STAT3 
sites found in its promoter region (−2000 +500 from TSS).The enrichment is evaluated with respect to all 
the genes in the chip that were detected above background in at least one sample. Cluster 7 showed 
a strong overrepresentation of putative STAT3 targets. This cluster includes 82 genes bearing one 
STAT3 binding site (stat3.1; p value 0.00082) and 54 genes with two binding sites (stat3.2; p value 
0.00043).  
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Figure S3. STAT3 regulates IRF4 expression in ALCL cells. TS-SUP-M2 S3S cells were grown in the 
absence (-DOX) or presence (+DOX) of doxycycline (1µg/mL) to induce STAT3 depletion. Pellet for 
RT-qPCR and western blot analyses were collected at 72 (D3), 96 (D4) and 120 (D5) h. (A–B) RT-
qPCR analysis shows progressive decrease of STAT3 and IRF4 mRNA levels after 72 and 96 h of 
doxycycline treatment, respectively. (B) RT-qPCR analysis shows progressive decrease of IRF4 
mRNA levels after 96 h of doxycycline treatment. Pellet were collected at 72 (D3), 96 (D4) and 120 
(D5) h. TS-SUP-M2 S3S were grown in the presence (+DOX) or absence (−DOX) of doxycycline (1 
µg/mL) for 120 h. TS-SUP-M2 S3S cells showed remarkable STAT3 and IRF4 downregulation after 5 
days treatment with doxycycline. (A) STAT3 silencing after 5 days treatment with doxycycline 
detected by RT-qPCR. (B) IRF4 mRNA levels significantly decreased following STAT3 
downregulation. (C) Western blot analysis showing progressive decrease of STAT3 and IRF4 
protein levels after doxycycline treatment. 
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Figure S4. Effects of Pomalidomide treatment in ALCL cell lines. (A) Cell viability and (B) 
proliferation were measured in different ALCL cell lines at the indicated time points after DMSO or 
Pomalidomide (10µM) treatment. T-ALL CCRF-CEM cells were used as negative control. Data are 
presented as mean ± SD (n = 5). Analysis of cell death and cell proliferation revealed that only TS-
SUP-M2 S3S cells were significantly sensitive to Pomalidomide treatment (**p < 0.01;***p < 0.001). (C) 
Western blot analysis of cells after Pomalidomide treatment at the indicated time points.  
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Figure S5. Effects of Pomalidomide combination with the BET family inhibitor JQ1 in TS-SUP-M2 
S3S and JB6 cell lines. Apoptosis and western blot analysis of TS-SUP-M2 S3 (A) and JB6 (B) cells 
treated with DMSO, Pomalidomide, the BET inhibitor JQ1, or the combination of the two drugs. 
Error bars represent the s.d. of triplicate measurements (**p < 0.01;***p < 0.001). Pellet for western 
blot were collected 48 hours after treatments. 
Table S1. List of Cluster 7 genes. Cluster 7 includes transcripts early down-regulated following 
inducible STAT3 KD in TS-SUP-M2cells 
TargetID ProbeID SEARCH_KEY CLUSTER ID 
−DOX 
AVG_Sig 
+DOX 
72 h 
Log2R 
+DOX 96 
h Log2R 
+DOX 
120 h 
Log2R 
+DOX 144 
h Log2R Oldexp 
HS.527588 870047 ILMN_100916 7 3049 −2.78 −3.68 −3.95 −4.05   
C13ORF16 3390041 ILMN_19109 7 8732 −2.54 −3.52 −4.19 −5.08   
FGB 7210240 ILMN_13882 7 2650 −2.40 −3.24 −3.46 −3.84 −1.92 
ZNF395 1980403 ILMN_17231 7 4559 −2.28 −1.62 −2.03 −2.81 −2.28 
TNFRSF9 5670440 ILMN_13404 7 870 −2.13 −1.97 −2.18 −2.06 −0.74 
LEF1 2810601 ILMN_30265 7 7327 −2.09 −2.90 −3.42 −3.80 −2.54 
SLC2A5 7560541 ILMN_14785 7 6049 −2.08 −1.91 −1.75 −2.25   
ANKRD37 240682 ILMN_2423 7 2756 −2.07 −1.36 −1.32 −2.45 −1.65 
UHRF2 2970612 ILMN_138390 7 2497 −2.02 −2.01 −1.64 −1.99 −1.30 
LEF1 4570255 ILMN_30265 7 6489 −1.99 −2.97 −3.39 −3.82 −2.54 
ICOS 2070037 ILMN_9996 7 13,683 −1.99 −3.00 −2.98 −3.38 −2.41 
PSCD4 6510524 ILMN_16536 7 8740 −1.98 −2.30 −2.51 −2.20 −1.49 
LOC196549 2710717 ILMN_17912 7 1588 −1.97 −1.57 −1.83 −2.44 −1.60 
FCRLB 4730204 ILMN_24322 7 4927 −1.93 −1.88 −1.47 −1.74 −1.06 
LOC145837 4050674 ILMN_30561 7 1311 −1.90 −2.33 −2.48 −2.49   
STARD13 3440184 ILMN_4567 7 2932 −1.89 −1.93 −2.38 −3.18 −1.13 
IL6R 5870685 ILMN_6641 7 940 −1.89 −2.17 −2.21 −2.58 −1.36 
SGK 4390450 ILMN_2451 7 5883 −1.85 −2.33 −2.56 −2.94 −2.20 
STAT3 5090619 ILMN_29673 7 15,774 −1.80 −1.96 −2.32 −2.75 −1.94 
SPTLC3 6590402 ILMN_90698 7 1223 −1.76 −1.77 −1.64 −2.17   
LOC158160 2030672 ILMN_21155 7 22,170 −1.76 −2.94 −3.47 −3.65 −0.81 
SPTLC3 3780743 ILMN_7329 7 1177 −1.75 −1.84 −1.85 −2.16   
UPK1B 4490068 ILMN_11904 7 7281 −1.72 −2.23 −3.19 −3.63 −2.24 
HS.560343 6400564 ILMN_114182 7 2546 −1.71 −1.90 −2.12 −1.86   
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STARD13 3190411 ILMN_4466 7 1160 −1.69 −1.63 −1.91 −2.36   
STAT3 2100484 ILMN_170837 7 4524 −1.68 −1.77 −2.20 −2.68   
ALB 650431 ILMN_28973 7 857 −1.67 −2.09 −2.16 −2.37   
HS.93739 4540446 ILMN_74213 7 670 −1.65 −1.58 −1.42 −1.69   
STAT3 4250538 ILMN_29673 7 4178 −1.61 −1.95 −2.25 −2.64 −1.94 
TMPRSS11D 2320168 ILMN_28873 7 2562 −1.60 −2.35 −2.57 −3.48 −1.94 
MMP20 2480390 ILMN_1399 7 747 −1.56 −1.69 −1.81 −2.17 −1.50 
HS.37648 4860280 ILMN_72502 7 1541 −1.53 −1.59 −1.69 −1.71   
IL10 6180093 ILMN_9173 7 878 −1.46 −1.63 −2.26 −2.25   
HSD17B7P2 7610142 ILMN_1267 7 4835 −1.44 −2.86 −3.41 −3.28 −2.21 
HS.448059 2510671 ILMN_93404 7 2244 −1.42 −1.56 −1.48 −1.68   
SLCO2B1 6580441 ILMN_1897 7 820 −1.42 −1.81 −1.72 −1.82 −1.08 
MEIS2 20358 ILMN_3095 7 1581 −1.41 −1.36 −1.07 −1.11 −1.36 
AXUD1 7560041 ILMN_6524 7 9353 −1.40 −1.07 −0.95 −1.08 −0.79 
IGSF11 5270102 ILMN_551 7 1617 −1.40 −1.45 −1.85 −2.38   
ABCA13 1780537 ILMN_19037 7 9378 −1.35 −0.64 −0.09 −0.07 −0.68 
TNFRSF21 3780092 ILMN_9651 7 10,608 −1.35 −1.15 −1.53 −1.74 −1.50 
HS.529631 7200286 ILMN_101314 7 1780 −1.33 −1.83 −1.59 −1.94   
FAM46C 6860347 ILMN_7706 7 8119 −1.32 −1.17 −0.69 −1.36 −0.84 
CXCR5 3890400 ILMN_19896 7 577 −1.32 −1.37 −1.35 −1.67   
CMAH 5550066 ILMN_13868 7 5192 −1.31 −1.21 −1.33 −1.92   
NSL1 4640370 ILMN_164300 7 701 −1.31 −1.65 −1.94 −1.91   
CD59 1410201 ILMN_1905 7 953 −1.30 −1.51 −1.14 −0.88   
FBXO32 1990079 ILMN_3809 7 5857 −1.30 −1.06 −0.48 −0.70 −0.72 
LOC642299 6020561 ILMN_31918 7 1926 −1.29 −1.51 −1.47 −1.72   
IQCG 70551 ILMN_26972 7 7879 −1.28 −1.91 −2.07 −1.88 −2.07 
RORA 1110180 ILMN_13528 7 2362 −1.28 −1.77 −1.95 −2.10 −1.55 
HS.36053 2940228 ILMN_72440 7 2285 −1.24 −1.86 −1.84 −2.24   
MYBPC2 5270100 ILMN_16419 7 10,920 −1.21 −1.91 −1.89 −2.22 −1.55 
CD5 5050347 ILMN_29547 7 1644 −1.20 −1.68 −2.15 −2.22 −1.25 
SOX2 5130156 ILMN_171554 7 1801 −1.20 −1.78 −1.66 −1.87   
NFIL3 5420564 ILMN_14880 7 3162 −1.19 −0.71 −0.69 −0.81 −1.19 
PHF21A 6580164 ILMN_28019 7 8593 −1.18 −0.71 −0.22 −0.29   
HS.190748 1260356 ILMN_81073 7 612 −1.17 −1.29 −1.37 −1.23   
LOC651621 630095 ILMN_45641 7 2196 −1.17 −2.06 −2.26 −2.29   
TGM2 2940446 ILMN_8134 7 18,359 −1.16 −0.77 −0.69 −0.68   
CERK 3060692 ILMN_2275 7 3138 −1.16 −0.79 −0.63 −0.85   
GZMB 1850523 ILMN_23555 7 40,169 −1.15 −2.45 −3.11 −3.45 −1.34 
VCL 70592 ILMN_26712 7 16,372 −1.13 −1.60 −1.21 −1.21   
CMAH 4250634 ILMN_13868 7 3642 −1.13 −1.36 −1.24 −1.83   
C9ORF38 50209 ILMN_36611 7 978 −1.12 −1.49 −1.48 −1.99   
SEMA4B 5080280 ILMN_25026 7 1832 −1.12 −0.47 −0.75 −0.70   
RGS16 1030102 ILMN_16445 7 5498 −1.11 −1.43 −2.25 −2.08 −1.65 
TNFRSF10D 830113 ILMN_17600 7 1101 −1.10 −1.15 −0.71 −0.77   
STAMBPL1 7150059 ILMN_1387 7 6426 −1.10 −0.23 0.08 −0.65   
EDG1 160754 ILMN_138993 7 581 −1.10 −1.35 −1.43 −1.62 −1.78 
CCDC46 6400161 ILMN_173004 7 2803 −1.10 −1.46 −0.98 −1.02   
RORA 3940703 ILMN_13528 7 808 −1.10 −1.59 −1.57 −1.72 −1.55 
ERC2 7150050 ILMN_17447 7 605 −1.10 −1.24 −0.65 −0.39 −0.60 
LOC440895 5310575 ILMN_44926 7 799 −1.10 −0.86 −0.82 −1.50   
ALB 5910010 ILMN_28973 7 581 −1.10 −1.58 −1.68 −1.44   
FLJ22447 1240653 ILMN_37423 7 1117 −1.09 −1.34 −1.43 −1.75   
CDK5RAP2 7570348 ILMN_9876 7 784 −1.09 −1.62 −1.69 −1.79 −0.98 
TNFRSF8 4850253 ILMN_21182 7 6392 −1.08 −0.95 −1.77 −2.34 −1.36 
C5ORF13 940471 ILMN_2442 7 13,584 −1.08 −1.11 −1.15 −1.18 −1.33 
BIRC3 5080021 ILMN_3897 7 2415 −1.07 −0.81 −0.24 0.07   
CFH 380424 ILMN_12111 7 3249 −1.06 −0.78 −0.01 0.61   
ANKRD22 4150270 ILMN_7804 7 390 −1.06 −0.72 −0.37 0.12   
ERO1L 4780671 ILMN_4958 7 3416 −1.05 −1.04 −0.61 −1.02 −0.69 
LOC650546 7210673 ILMN_35170 7 1731 −1.05 −1.30 −1.38 −2.39   
FCGR2A 1990278 ILMN_26366 7 558 −1.04 −1.16 −1.19 −1.14   
HS.368984 5490192 ILMN_87858 7 655 −1.02 −1.19 −1.01 −0.70   
N4BP2L1 620112 ILMN_24274 7 393 −1.01 −0.79 −0.71 −1.10 −0.74 
MTUS1 3800017 ILMN_5924 7 1134 −1.00 −1.12 −1.51 −1.69   
SOX2 5080273 ILMN_13292 7 622 −1.00 −1.22 −1.22 −1.35   
KBTBD11 5050093 ILMN_20625 7 5058 −1.00 −1.78 −1.94 −2.14 −1.22 
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NIN 5310717 ILMN_3063 7 4443 −0.99 −1.05 −0.89 −1.01 −0.62 
ZBTB32 7560273 ILMN_2617 7 2142 −0.99 −0.49 −0.74 −1.39   
KLF9 3390292 ILMN_2670 7 2736 −0.98 −1.40 −1.07 −1.08 −1.14 
AQP9 160494 ILMN_15164 7 13,906 −0.97 −1.31 −1.44 −1.95 −1.63 
HS.580444 840452 ILMN_132625 7 517 −0.97 −1.31 −1.40 −1.62   
DMBX1 2940187 ILMN_13566 7 1708 −0.97 −0.43 −1.01 −1.08 −1.23 
MYO10 4670131 ILMN_28857 7 621 −0.97 −1.13 −0.79 −0.76 −1.70 
IKZF1 730482 ILMN_22185 7 2966 −0.95 −0.65 −0.36 −1.26 −0.68 
NIN 2190196 ILMN_3320 7 694 −0.94 −0.99 −1.08 −0.83   
PLOD2 7040477 ILMN_14675 7 14,800 −0.94 −0.81 −0.66 −1.06 −0.78 
GPLD1 3180379 ILMN_20927 7 557 −0.93 −0.87 −1.00 −0.84 −0.81 
C13ORF18 7000079 ILMN_19053 7 2630 −0.92 −1.57 −1.57 −1.99 −1.19 
LOC647691 4920768 ILMN_46634 7 1159 −0.92 −0.82 −1.19 −1.53   
PRRX2 4150204 ILMN_9456 7 3810 −0.90 −1.14 −1.01 −1.51 −1.26 
NLRP7 5670129 ILMN_2155 7 9786 −0.89 −0.45 −0.68 −1.02   
HELLS 7040161 ILMN_164061 7 1893 −0.89 −0.82 −1.44 −1.92   
KIAA1671 3120474 ILMN_42090 7 2311 −0.88 −1.51 −1.61 −1.40   
FLJ35880 1170241 ILMN_3282 7 744 −0.88 −0.87 −0.90 −1.42   
NLRP7 6180600 ILMN_10029 7 3380 −0.88 −0.59 −0.58 −1.18   
PLOD2 4640187 ILMN_25982 7 2357 −0.88 −0.93 −0.74 −1.41   
IRF4 6980370 ILMN_12414 7 1389 −0.88 −0.81 −1.48 −1.81 −1.67 
HS.205745 2640497 ILMN_81914 7 713 −0.87 −1.11 −0.44 −0.34   
DICER1 5390433 ILMN_1996 7 1944 −0.87 −0.85 −0.55 −1.12 −0.94 
HS.566469 1500133 ILMN_118789 7 408 −0.87 −0.90 −0.93 −1.19   
SLC19A3 4540593 ILMN_25079 7 926 −0.86 −0.98 −1.38 −1.92 −0.74 
TIPARP 6760546 ILMN_4419 7 10,212 −0.86 −1.44 −1.69 −2.14 −1.13 
SF3B3 1090239 ILMN_18316 7 9050 −0.85 −1.32 −1.33 −1.77   
LOC442597 2710121 ILMN_42881 7 69,455 −0.85 −1.33 −1.26 −1.51   
CACNB2 7100154 ILMN_2192 7 828 −0.85 −1.31 −1.64 −2.09 −1.24 
SLC26A4 5900358 ILMN_23896 7 5740 −0.84 −0.57 −1.00 −1.57 −0.76 
IL1RAP 3800427 ILMN_8626 7 497 −0.84 −1.15 −1.30 −1.36 −1.48 
CDK5RAP2 4260017 ILMN_3896 7 26,180 −0.83 −0.98 −1.23 −1.07 −1.48 
CSGALNACT2 1980092 ILMN_11419 7 1414 −0.83 −1.02 −0.80 −1.11 −1.26 
LOC650546 4180148 ILMN_35170 7 2183 −0.83 −1.12 −1.51 −1.96   
HS.566966 670411 ILMN_119192 7 672 −0.82 −1.53 −1.67 −1.73   
ZNF672 6330646 ILMN_24640 7 4068 −0.82 −1.04 −0.85 −1.13   
ZDHHC19 830615 ILMN_27596 7 492 −0.82 −0.67 −0.97 −1.21 −0.76 
SLCO2B1 1400121 ILMN_1897 7 439 −0.81 −1.02 −0.88 −0.66 −1.08 
C13ORF18 2850286 ILMN_19053 7 3309 −0.81 −1.53 −1.57 −1.93 −1.19 
ATF3 4780128 ILMN_182693 7 2392 −0.79 −1.12 −1.49 −0.96   
ITIH5 5050121 ILMN_9175 7 442 −0.78 −0.85 −1.03 −1.10 −0.95 
CSF3R 6270114 ILMN_21047 7 1542 −0.78 −1.42 −1.04 −0.86   
CCDC34 3450408 ILMN_2645 7 10256 −0.77 −0.79 −1.19 −1.24 −1.55 
FAM123A 2760291 ILMN_26739 7 3304 −0.76 −1.21 −1.55 −2.32   
HS.10862 1940563 ILMN_71180 7 17,896 −0.76 −0.67 −0.77 −1.15   
BATF3 5900253 ILMN_7180 7 26,954 −0.76 −1.14 −1.40 −1.66 −1.15 
ASPH 2370450 ILMN_182157 7 2107 −0.76 −1.01 −1.49 −1.51   
TSHZ3 5870424 ILMN_19320 7 8306 −0.75 −0.66 −0.64 −1.26 −0.72 
RNF144 3450136 ILMN_15740 7 3234 −0.74 −0.88 −0.70 −1.15   
AGTPBP1 4760427 ILMN_12151 7 2461 −0.74 −0.96 −1.18 −1.16 −1.14 
BATF 6220195 ILMN_3307 7 6380 −0.73 −1.04 −1.15 −1.29   
RUNX1 7400368 ILMN_19125 7 1194 −0.72 −0.58 −0.60 −1.00   
PCCA 4730309 ILMN_6045 7 3934 −0.72 −0.93 −1.11 −0.94   
IL6R 1780603 ILMN_22419 7 329 −0.70 −0.96 −0.84 −1.00 −0.61 
FAM113A 290296 ILMN_22766 7 2048 −0.70 −0.75 −0.83 −1.30   
DDX12 2120039 ILMN_33363 7 565 −0.70 −0.89 −1.16 −1.22   
C1ORF112 940240 ILMN_5134 7 2455 −0.68 −0.80 −0.94 −1.37 −0.95 
MCM10 6580685 ILMN_2483 7 1471 −0.68 −0.94 −1.40 −1.86 −1.65 
PASK 4150100 ILMN_19873 7 1133 −0.68 −0.85 −1.16 −1.60 −0.88 
TNFAIP3 3360681 ILMN_2315 7 683 −0.68 −0.82 −1.08 −0.67   
VCL 2900068 ILMN_26712 7 797 −0.67 −0.79 −1.09 −0.93   
LOC653778 830639 ILMN_32201 7 6816 −0.67 −0.77 −0.66 −1.39   
CMTM7 2140239 ILMN_8486 7 24,363 −0.67 −0.74 −0.73 −1.20 −1.27 
SLC1A3 4210403 ILMN_17250 7 494 −0.67 −1.21 −0.92 −1.45 −0.77 
ACPP 2680725 ILMN_23186 7 836 −0.66 −1.03 −0.83 −0.73 −0.75 
CACNB2 2850458 ILMN_2192 7 930 −0.66 −1.09 −1.32 −1.94 −1.24 
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GNAL 4200709 ILMN_29214 7 918 −0.65 −0.72 −1.17 −1.17   
CCDC34 7040184 ILMN_2645 7 32,783 −0.65 −0.84 −0.90 −1.35 −1.55 
NFKBIA 4280113 ILMN_6745 7 20,541 −0.64 −1.25 −1.24 −1.01 −1.33 
LOC654103 7320707 ILMN_37027 7 10,798 −0.64 −0.75 −0.71 −1.41   
FAM29A 4760615 ILMN_3594 7 637 −0.63 −0.82 −0.86 −1.18 −0.71 
HS.566835 4880398 ILMN_119083 7 960 −0.63 −0.76 −0.70 −1.38   
ACMSD 20041 ILMN_21475 7 1130 −0.63 −1.42 −1.57 −1.36   
RAD54L 1980291 ILMN_1278 7 1080 −0.63 −1.04 −1.26 −1.69 −1.71 
DPAGT1 2680176 ILMN_10306 7 1281 −0.63 −0.49 −0.76 −1.09 −0.65 
CLIP1 2260066 ILMN_179647 7 8485 −0.62 −0.87 −1.03 −1.03   
LOC653513 5820167 ILMN_43919 7 1788 −0.62 −0.78 −1.23 −1.41   
ARID2 7100044 ILMN_163259 7 887 −0.61 −0.56 −0.59 −1.11   
MAN1C1 6280184 ILMN_12633 7 542 −0.60 −1.03 −1.15 −1.00   
LOC440359 5870307 ILMN_34340 7 10,799 −0.60 −0.67 −1.02 −1.50   
HNRNPA3 1440592 ILMN_5256 7 3138 −0.59 −1.09 −1.17 −1.63 −0.66 
NOD1 7610390 ILMN_10741 7 603 −0.58 −1.07 −1.00 −0.97 −0.63 
NBL1 5090156 ILMN_20462 7 6674 −0.58 −0.77 −0.98 −1.33   
USP32 5290369 ILMN_26659 7 1319 −0.57 −1.00 −1.18 −1.22 −1.20 
MAPK14 4860600 ILMN_17267 7 929 −0.57 −0.47 −0.72 −1.06 −0.88 
HELLS 4540768 ILMN_3656 7 977 −0.56 −1.06 −1.20 −1.64 −0.93 
GADD45B 4920110 ILMN_138334 7 1555 −0.56 −0.78 −1.11 −1.09   
PIH1D1 5910202 ILMN_10897 7 3009 −0.56 −0.74 −0.90 −1.04 −0.88 
ARID5B 1410408 ILMN_17477 7 6846 −0.56 −0.88 −1.21 −1.48   
ABHD3 5050241 ILMN_4359 7 1158 −0.56 −0.73 −0.59 −1.20   
FES 4120689 ILMN_27340 7 559 −0.56 −1.10 −1.50 −1.53   
PCNA 2510348 ILMN_6858 7 579 −0.56 −0.85 −0.99 −1.08 −0.81 
AK3L1 160148 ILMN_28560 7 19,298 −0.55 −0.67 −0.77 −1.22   
POLD3 4590608 ILMN_24871 7 1295 −0.54 −1.04 −1.04 −1.63 −0.95 
ANKRD32 6380747 ILMN_15362 7 1552 −0.54 −0.67 −0.57 −1.07 −0.60 
DDX23 5090450 ILMN_2003 7 3819 −0.53 −0.52 −0.83 −1.05 −0.67 
LOC654189 5700671 ILMN_30702 7 995 −0.52 −0.80 −0.62 −1.30   
CMTM7 4290403 ILMN_8951 7 1952 −0.52 −0.82 −0.92 −1.36   
SAPS3 2850273 ILMN_6618 7 2917 −0.51 −1.06 −1.01 −0.79 −0.73 
IMPA2 2340241 ILMN_19881 7 6053 −0.51 −0.62 −0.92 −1.03 −1.18 
MCC 2480669 ILMN_17732 7 434 −0.50 −0.89 −0.84 −1.02   
HSD17B7 3420328 ILMN_5318 7 30,246 −0.50 −0.71 −0.68 −1.09   
TOPBP1 870601 ILMN_24939 7 4008 −0.49 −0.90 −1.00 −1.22 −0.72 
UCHL5IP 1090370 ILMN_27285 7 8570 −0.49 −1.15 −1.34 −1.78   
PMP22 7560138 ILMN_5694 7 14,585 −0.48 −0.64 −0.53 −1.02 −0.71 
EME1 1260398 ILMN_3574 7 1147 −0.48 −0.72 −0.98 −1.40 −1.22 
EXO1 2690458 ILMN_25997 7 707 −0.48 −1.00 −1.28 −1.36   
CCDC4 5890554 ILMN_1131 7 928 −0.47 −1.09 −1.29 −1.09   
ZNF138 360370 ILMN_36856 7 1182 −0.46 −0.71 −0.67 −1.23   
DICER1 5130091 ILMN_1996 7 8484 −0.46 −0.82 −0.95 −1.25 −0.94 
HADH 6290709 ILMN_13258 7 8327 −0.45 −0.74 −0.67 −1.04 −0.73 
TMEM106C 1430537 ILMN_7003 7 11,234 −0.45 −0.66 −0.92 −1.04 −0.64 
PLOD2 460338 ILMN_14675 7 612 −0.44 −0.84 −0.56 −1.18 −0.78 
PDS5B 5220575 ILMN_13136 7 2131 −0.44 −0.64 −0.73 −1.03   
PDS5B 870167 ILMN_20213 7 1213 −0.42 −0.78 −0.92 −1.20 −0.78 
TNPO1 5080482 ILMN_18758 7 5142 −0.42 −1.08 −0.93 −1.42   
HS.135668 3830066 ILMN_77684 7 436 −0.41 −0.86 −0.70 −1.01   
CEP152 2340164 ILMN_570 7 1068 −0.41 −0.84 −0.94 −1.39 −1.47 
FLJ13305 5870072 ILMN_5829 7 1312 −0.39 −0.62 −0.94 −1.08   
FBXO5 5670255 ILMN_9763 7 1243 −0.39 −1.22 −1.35 −1.46 −1.46 
CHAF1A 2120097 ILMN_24131 7 775 −0.38 −0.87 −1.02 −1.32 −0.97 
FANCD2 3610022 ILMN_12871 7 451 −0.38 −0.73 −1.02 −1.06 −0.93 
SPRYD5 4880204 ILMN_14013 7 1048 −0.37 −1.04 −1.30 −1.18   
DNA2 6380452 ILMN_172479 7 872 −0.37 −0.69 −0.90 −1.13   
SIN3A 6420017 ILMN_14108 7 4662 −0.37 −0.69 −0.77 −1.10 −0.72 
TGIF2 1340020 ILMN_25134 7 1540 −0.37 −0.71 −0.47 −1.00   
ITK 7560632 ILMN_23317 7 1572 −0.37 −0.69 −1.05 −0.79   
FAM80A 6840619 ILMN_12396 7 669 −0.36 −0.91 −0.92 −1.15   
CDK2 2350286 ILMN_12332 7 1377 −0.35 −0.90 −0.93 −1.14 −1.13 
CACNB2 7210521 ILMN_24772 7 326 −0.35 −0.50 −0.68 −1.00   
RTTN 6400632 ILMN_5471 7 2581 −0.34 −0.88 −0.81 −1.10   
PDK3 110347 ILMN_15297 7 1622 −0.33 −0.67 −0.78 −1.07   
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CCNF 3130541 ILMN_27253 7 7467 −0.31 −0.78 −0.80 −1.21 −0.96 
MTHFS 6560066 ILMN_1014 7 14,508 −0.31 −0.61 −0.78 −1.04 −0.66 
SLC39A10 5960332 ILMN_13415 7 1054 −0.31 −0.61 −0.61 −1.02   
POLA2 4920537 ILMN_8864 7 5588 −0.30 −0.58 −0.71 −1.01 −0.82 
SLC37A4 5130577 ILMN_24454 7 5049 −0.28 −0.87 −0.82 −1.25 −0.84 
NUCKS1 1450753 ILMN_17108 7 1290 −0.25 −0.97 −0.87 −1.38   
MASTL 580470 ILMN_7073 7 957 −0.23 −0.92 −0.84 −1.06 −1.06 
SHMT1 2690528 ILMN_17710 7 3321 −0.19 −0.75 −0.64 −1.04 −0.71 
FAM76B 6130273 ILMN_22478 7 1407 −0.18 −0.89 −0.69 −1.15   
AVG: Average. 
Table S2. Cluster 7 genes selected for functional screening with shRNA. 
 
Table S3. Schematic result of the functional shRNA screening on cluster 7 genes. Positive hits were 
selected according to the following criteria: more than one shRNA sequence was able to reduce 
target mRNA levels by at least 70%; there was a correlation between the proportion of gene 
silencing and the phenotype. For genes showing “strong” phenotype, a “rescue” experiment 
expressing a shRNA-resistant open reading frame was performed (ITK and IRF4 highlighted in 
black box). 
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Table S4. List of shRNA sequences utilized in the screening. For each gene, 5 shRNA sequences 
from the TRC library (Sigma-Aldrich) were tested. 
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Table S5. Primer sequences used in the present study. 
Gene Name Forward Primers Reverse Primers 
TPARP 5′-CCACACCACCCTCTAGCAAT-3′ 5′-CTTTCAGACCCCGAGAGTTG-3′ 
ITK 5′-CGATTCCATCCCTCTTCTCA-3′ 5′-TTCTGCCTCCCAAAACAAAC-3′ 
TNFRSF9 5′-CACTCTGTTGCTGGTCCTCA-3′ 5′-GCGCTGGAGAAACTATTTGG-3′ 
UPK1B 5′-CCCTCCAAACAATGATGACC-3′ 5′-CCTCTGCCGGAGAAACAG-3′ 
ATF3 5′-AAGGAAAAAGAGGCGACGAG-3′ 5′-GCTGCTTCTCGTTCTTGAGC-3′ 
SNFT 5′-AGCCCTGAGGATGATGACAG-3′ 5′-GTTTTCTTGCTCCAGGCTCTC-3′ 
IRF4 5′-ACCCCTACACCATGACAACG-3′ 5′-GTCCAAACGTCATGGGACAT-3′ 
SOX2 5′-CTACGACGTGAGCGCCCTGC-3′ 5′-GCCAAGAGCCATGCCAGGGG-3′ 
UHRF2 5′-ACTGGCTGGTGGATTTGCGGA-3′ 5′-CCAGTCTTCCACCCGGTATCTGGA-3′ 
FGB 5′-GGGCTCGTCCAGCCAAAGCA-3′ 5′-ACACCCCCAGGTCTGGGTCA-3′ 
MEIS2 5′-GCCAAACGTCCCCGGCAAGA-3′ 5′-AGCGGGAACCCCTACTCCGT-3′ 
ICOS 5′-GTGCTCACTGGGAGTGGAAT-3′ 5′-GTCAACTGGGGTTCAGCAAT-3′ 
Il1RAP 5′-TGGTTGTTCTAAGCCCCAAC-3′ 5′-ACCTGCCCTGTGGATACTTG-3′ 
STAT3 5′-CTGCTCCAGGTACCGTGTGT-3′ 5′-CCTCTGCCGGAGAAACAG-3′ 
TNFRSF8 5′-GTCACCCACCTGACATCACC-3′ 5′-CCATGACATCCACTGTTCCA-3′ 
GAPDH 5′-AAGGAGAGCTCAAGGTCAGC-3′ 5′-GGGAGTAGGGACCTCCTGTT-3′ 
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